BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/11/2025 8:20:58 AM | Browse: 2 | Download: 1
 |
Received |
|
2025-08-04 11:21 |
|
Peer-Review Started |
|
2025-08-04 11:21 |
|
First Decision by Editorial Office Director |
|
2025-08-15 08:53 |
|
Return for Revision |
|
2025-08-15 08:53 |
|
Revised |
|
2025-08-27 07:01 |
|
Publication Fee Transferred |
|
2025-08-28 06:00 |
|
Second Decision by Editor |
|
2025-11-03 02:43 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-03 09:55 |
|
Articles in Press |
|
2025-11-03 09:55 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-11-28 03:30 |
|
Publish the Manuscript Online |
|
2025-12-11 08:20 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xian-Yang Meng, Yu-Mei Cai, Ning-Ning Sun, Wen-Hua Zhang, Rui-Xue Cui, Long Zhang, Cheng-Cheng Zheng, Zhen Sun, Wei-Xuan Luo and Feng-Wei Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Feng-Wei Wang, MD, PhD, Department of Oncology, Tianjin Union Medical Center of Nankai University, No. 190 Jieyuan Road, Tianjin 300121, China. wfengwei2004@163.com |
| Key Words |
Immune checkpoint inhibitor; Fruquintinib; Docetaxel; Advanced microsatellite stable/proficient mismatch repair colorectal cancer; Programmed death 1 |
| Core Tip |
This study aimed to evaluate the efficacy and safety of a novel triple-combination regimen - programmed death 1 inhibitor + fruquintinib + docetaxel - as a third-line treatment for advanced microsatellite stable/proficient mismatch repair colorectal cancer. Primary endpoints included progression-free survival and disease control rate. Intention-to-treat analysis showed median progression-free survival 7.0 months, median overall survival 18.5 months, disease control rate 61.5%, with manageable toxicity. This study preliminarily validates the synergistic effect of programmed death 1 inhibitors combined with fruquintinib and docetaxel in microsatellite stable colorectal cancer, providing a novel strategy with translational significance for later-line treatment in advanced patients. |
| Publish Date |
2025-12-11 08:20 |
| Citation |
Meng XY, Cai YM, Sun NN, Zhang WH, Cui RX, Zhang L, Zheng CC, Sun Z, Luo WX, Wang FW. Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer. World J Gastrointest Oncol 2025; 17(12): 112548 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i12/112548.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i12.112548 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
